Identification | Back Directory | [Name]
PF-7006 | [CAS]
2771955-09-8 | [Synonyms]
PF-7006 7H-Pyrrolo[2,3-d]pyrimidine-5-carbonitrile, 2-[[2-methyl-6-(4-morpholinyl)-3-pyridinyl]amino]-4-[(tetrahydro-2H-pyran-4-yl)amino]- | [Molecular Formula]
C22H26N8O2 | [MOL File]
2771955-09-8.mol | [Molecular Weight]
434.5 |
Hazard Information | Back Directory | [Uses]
PF-7006 is an Mps1 kinase inhibitor with a Ki value of 0.27 nM and an IC50 value of 2.5 nM. PF-7006 interferes with cell cycle checkpoints by inhibiting the catalytic activity of Mps1, reducing histone H3 levels, and shortening the duration of mitosis, leading to apoptosis in cancer cells. Combined use of PF-7006 with Palbociclib (HY-50767) increases cancer cell tolerance to PF-7006. PF-7006 can be used for breast cancer research[1]. | [References]
[1] Martinez R, et al. Mitotic Checkpoint Kinase Mps1 Has a Role in Normal Physiology which Impacts Clinical Utility. PLoS One. 2015 Sep 23;10(9):e0138616. DOI:10.1371/journal.pone.0138616 |
|
|